Myung In Pharm Co

Myung In Pharm Co EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Myung In Pharm Co (317450.KS) as of Nov 18, 2026 is 92.50 B KRW. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 96.11 B KRW — a change of -3.76% (lower).

EBITDA

92.50 BKRW

YoY

-3.76%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Myung In Pharm Co is 2025 92.50 B KRW. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Myung In Pharm Co was 2024 96.11 B KRW. It decreases by -3.76% lower compared to the previous year.

The Myung In Pharm Co EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2023
86.09 B KRW
Jan 1, 2024
96.11 B KRW
Jan 1, 2025
92.50 B KRW
The Myung In Pharm Co EBITDA history
YEAREBITDAYoY
92.50 BKRW-3.76%
96.11 BKRW+11.64%
86.09 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Myung In Pharm Co Stock analysis

What does Myung In Pharm Co do? Myung In Pharm Co., Ltd. generates revenue through the manufacture and sale of prescription drugs for neurology and psychiatry, including stroke and Parkinson’s disease treatments, schizophrenia, and depression therapies. The company primarily targets domestic and overseas markets, distributing its products under its own brand for neurological and psychiatric conditions. General pharmaceuticals such as dental, oral, digestive system treatments, and other related products form additional revenue streams within its domestic and international sales channels. The firm focuses on prescription drug segments, with key products addressing stroke, Parkinson’s disease, schizophrenia, and depression. These treatments are sold directly to healthcare providers and pharmacies in both domestic and overseas markets. The company also offers general pharmaceuticals like dental and oral treatments, alongside digestive system therapies, contributing to its diversified product portfolio across multiple therapeutic areas. Myung In Pharm’s business model relies on selling branded prescription medications for specific neurological and psychiatric conditions, alongside general pharmaceuticals. Its domestic and overseas market presence ensures consistent revenue from both regional and global healthcare sectors, with no additional details on specific customer segments or pricing strategies disclosed in the provided description. Myung In Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Myung In Pharm Co stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Myung In Pharm Co is 92.50 B KRW in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Myung In Pharm Co changed from 96.11 B KRW to 92.50 B KRW, representing a -3.76% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Myung In Pharm Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Myung In Pharm Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Myung In Pharm Co

All Key Metrics — Myung In Pharm Co